ADAMTS‐13 and von Willebrand factor predict venous thromboembolism in patients with cancer

Pépin, Marion; Kleinjan, A.; Hajage, David; Büller, Harry R.; Nisio, Marcello Di; Kamphuisen, Pieter Willem; Salomon, Laurence; Veyradier, Agnès; Stépanian, Alain; Mahé, Isabelle

doi:10.1111/jth.13205

Cited by 69 publications

(78 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Overall, this may identify VWF as a possible laboratory tool for risk stratification of cancer patients prone to develop VTE. These results are in accordance with Pépin et al, who found statistically significant increased levels of VWF in cancer patients with VTE compared to cancer patients without VTE. Interestingly, in their patient cohort there was no significant difference in the levels of ADAMTS‐13 or ADAMTS13/VWF between cancer patients with VTE or without.…”

Section: Discussionsupporting

confidence: 92%

“…Cancer patients have been shown to have higher VWF levels and lower ADAMTS‐13 levels than the general population, often also in a stage‐dependent intensity …”

Section: Introductionmentioning

confidence: 99%

“…In a recent study VWF and ADAMTS‐13 were shown to be associated with occurrence of VTE in cancer patients, with ADAMTS‐13 exhibiting predictive potential in risk scores . Patients with VTE or history of VTE have been repeatedly shown to have higher mean levels of VWF, however, patients with underlying malignancy have always been excluded.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The role of ADAMTS‐13 and von Willebrand factor in cancer patients: Results from the Vienna Cancer and Thrombosis Study

Obermeier

Riedl

et al. 2019

Research and Practice in Thrombosis and Haemostasis

View full text Add to dashboard Cite

Cancer is associated with increased risk of developing venous thrombosis. Cancer patients were studied for ADAMTS‐13 and VWF levels and occurrence of venous thrombosis. Increased VWF in cancer patients is associated with a higher risk of venous thrombosis. Low levels of ADAMTS‐13 and/or increased VWF in cancer patients are associated with worse survival. Background Cancer‐associated venous thromboembolism (VTE) is an important complication in the course of a malignant disease. Low ADAMTS‐13 (a disintegrin‐like and metalloproteinase with thrombospondin type 1 motif 13) and increased von Willebrand Factor (VWF) levels in cancer patients have been described numerously. Objectives Investigation of the influence of ADAMTS‐13 and VWF on the probability of VTE and survival in malignancy. Patients/Methods In the framework of the ongoing prospective Cancer and Thrombosis Study (CATS) ADAMTS‐13 activity and VWF antigen levels were investigated in cancer patients. Results In total, 795 patients with various tumor types (364 female/431 male, median age 62 years) were included; of those, 56 developed VTE and 359 patients died during a median follow‐up time of 730 days. The hazard ratio (HR) of VTE per doubling of VWF level was 1.56 (95% confidence interval [CI] 1.13‐2.16) in multivariable competing risk analysis. ADAMTS‐13 levels showed no correlation with the incidence of VTE in univariate competing risk analysis. The HR of mortality per doubling of VWF level was 1.46 (95% CI 1.28‐1.66) and per SD increment of ADAMTS‐13was 0.90 (95% CI 0.81‐1.00) in multivariable Cox regression analysis. Patients with VWF >75th percentile and concomitant low (<25th percentile) or medium (25‐75th percentile) ADAMTS‐13 values had the highest probability of mortality (HR 4.31 and 4.75, respectively). Conclusions High VWF levels were significantly associated with the risk of developing VTE in cancer patients, whereas ADAMTS‐13 was not. Low ADAMTS‐13 and increased VWF levels were independently associated with worse overall survival.

show abstract

Section: Discussionsupporting

confidence: 92%

“…Cancer patients have been shown to have higher VWF levels and lower ADAMTS‐13 levels than the general population, often also in a stage‐dependent intensity …”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The role of ADAMTS‐13 and von Willebrand factor in cancer patients: Results from the Vienna Cancer and Thrombosis Study

Obermeier

Riedl

et al. 2019

Research and Practice in Thrombosis and Haemostasis

View full text Add to dashboard Cite

show abstract

“…acute lymphoblastic leukemia, colorectal cancer, bladder cancer, and ovarian cancer . Higher levels have been found to correlate with cancer stage and VTE occurrence in cancer patients . VWF also plays a role in hemostasis by binding FVIII and thus protecting the coagulation factor from proteolytic degradation and prolonging its half‐life in the circulation.…”

Section: Discussionmentioning

confidence: 99%

Coagulation and inflammation in long‐term cancer survivors: results from the adult population

Panova‐Noeva

Schulz

Arnold

et al. 2018

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

Background The advances in cancer treatment and detection of early cancer have resulted in a steady increase in the number of of cancer survivors over the years. However, because of the long-term toxic effects of chemotherapy and radiotherapy, the incidence of cardiovascular disease (CVD) is increasing in survivors. Objectives To investigate traditional cardiovascular risk factors (CVRFs), inflammation and the coagulation profile in long-term cancer survivors (cancer diagnosis ≥ 5 years) from a large adult population-based study sample. Methods The presence of cardiovascular risk factors (CVRFs) and laboratory markers were compared in individuals with (n = 723) and without (n = 13626) a long-term history of cancer from the Gutenberg Health Study. Data on coagulation factors, D-dimer and von Willebrand factor (VWF) activity were available for 4974 individuals (n = 244 cancer survivors). Results In multivariable regression models, a history of cancer was, independently of CVRFs and CVD, associated with higher fibrinogen levels (β 6.99, 95% confidence interval [CI] 1.16-12.8), VWF activity (β 5.08, 95% CI 0.02-10.1), and antithrombin activity (β 1.85, 95% CI 0.44-3.27). Cancer survivors with CVD showed notably higher VWF activity than individuals with CVD without a history of cancer, with a difference in the means of 23.0 (7.9-38.1). Multivariate Cox regression analysis, adjusted for CVRFs, confirmed that a long-term history of cancer is associated with a 72% higher mortality. Increased mortality in cancer survivors was dependent on fibrinogen level and VWF activity level. Conclusion Cancer survivors showed a worse inflammation and coagulation profile than individuals without a history of cancer. Overall mortality in long-term cancer survivors was increased independently of traditional CVRFs. These results underline the need to further investigate plasma biomarkers as complementary cardiovascular risk predictors in cancer survivors.

show abstract

“…High levels of von Willebrand factor (vWF) are a risk factor for thrombus formation and progression. In 1971, it was first identified that the decrease of vWF could cause the occurrence of hemorrhagic diseases and, with the continuous studies on vWF, it was shown that the increase of vWF could promote the formation of thrombosis. vWF is synthesized by vascular endothelial cells and marrow megakaryocytes, which can connect collagen and platelets, initiate the coagulation process, and play a bridging role in thrombus.…”

Section: Discussionmentioning

confidence: 99%

Correlation between an ABO Blood Group and Primary Femoral Head Necrosis: A Case–Control Study

Yang

Zeng

et al. 2020

Orthopaedic Surgery

View full text Add to dashboard Cite

Objective: To investigate the relationship between primary femoral head necrosis (ONFH) and an ABO blood group.Methods: This study was a retrospective case-control trial. An analysis of the clinical data of an ABO blood group with 516 patients (case group) with ONFH and 489 limb-fracture patients (control group) without previous hip pain was obtained from the Second Hospital of Shanxi Medical University from November 2015 to November 2018. The clinical data included gender, age, height, weight, a history of smoking, alcohol abuse, prior medical history, hormone use, and ABO blood type. A logistic regression model was used for univariate and multivariate analysis.Results: From November 2015 to November 2018, there were 267 males and 249 females in the 516 cases of ONFH in the case group. The control group included 289 males and 200 females. In terms of age, the average age of the case group was significantly lower than that of the control group. In terms of body mass index (BMI), the BMI of the case group was significantly higher than that of the control group (P < 0.05). From the previous medical history of patients in the two groups (coronary heart disease, hypertension, cerebrovascular disease, diabetes, and peripheral vascular disease), there was no significant difference between the two groups from a statistical perspective (P < 0.05). However, according to the risk factors of ONFH (smoking, alcohol abuse, hyperlipidemia, and hormone-use history), there were significant differences between the case group and the control group. There was no statistical difference in the quantitative distribution ratio of the four blood types -A, B, O, and ABbetween the case group and the control group. The outcomes of logistic multiple regression analysis presented that there was no significant correlation between the occurrence of ONFH and blood type A, B, AB, and O (P > 0.05). However, there are significant differences in the disease progression between the different blood types. There was a significant difference in the progression of disease between type A and type O. Among them, patients with ONFH and type A blood had the fastest progression with an average of 2.318 years, and the slowest progression was found in type O blood with an average of 5.15 years. Conclusions:The ABO blood group has no correlation with the occurrence of ONFH, but the ABO blood type is closely related to the disease progression of ONFH.

show abstract

ADAMTS‐13 and von Willebrand factor predict venous thromboembolism in patients with cancer

Cited by 69 publications

References 52 publications

The role of ADAMTS‐13 and von Willebrand factor in cancer patients: Results from the Vienna Cancer and Thrombosis Study

The role of ADAMTS‐13 and von Willebrand factor in cancer patients: Results from the Vienna Cancer and Thrombosis Study

Coagulation and inflammation in long‐term cancer survivors: results from the adult population

Correlation between an ABO Blood Group and Primary Femoral Head Necrosis: A Case–Control Study

Contact Info

Product

Resources

About